
News|Articles|October 1, 2004
High-dose simvastatin fails to achieve primary end point in trial of ACS
Initiating high-dose simvastatin (Zocor, Merck) early after an acute coronary syndrome (ACS) event does not result in significantly superior clinical outcomes compared to delayed initiation of low-dose simvastatin.This major finding of phase Z of the A to Z Trial is in contrast to the results of 2 previous clinical trials in which aggressive therapy with atorvastatin (Lipitor, Pfizer) was found to be superior to less aggressive statin therapy in reducing the risk of adverse clinical events in ACS patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rural health is ailing. Is $50 billion enough to heal it?
2
GLP-1 medications are linked to hair loss in Type 2 diabetes
3
FDA clears Mimrylo, a first-in-class therapy for polycythemia vera
4
Recombinant shingles vaccine linked to lower cardiovascular disease risk
5























